Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 May 8;5(5):e1221. doi: 10.1038/cddis.2014.176

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2014 Macmillan Publishers Limited

Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/

PMC Copyright notice

PALMD is promoted by p53 in response to DNA damage. SaOS2 (p53-deficient) and U2OS (p53-proficient) cells were treated with ADR (ADR or A) or left untreated (control or C). (a) mRNA expression of PALMD in response to DNA damage. Data represent fold change of PALMD in ADR-treated cells relative to the control. *P<0.01. (b) Protein expression level of PALMD in response to ADR exposure. Cell lysates were immunoblotted against anti-PALMD (top panel), anti-phospho-p53(Ser46) (second panel), anti-p53 (third panel), or anti-tubulin (bottom panel). (c) The binding of endogenously expressing p53 onto PALMD under stressed condition. Cell lysates were immunoprecipitated with anti-p53 or anti-immunoglobulin (Ig)G. ChIP assay and subsequent real-time PCR were performed. The data were normalized with the level of input control. *P<0.01. (d) PALMD level in p53-depleted cells. U2OS cells were transfected with non-silencing siRNA or p53 siRNA (sip53). Cells were treated or left untreated with ADR and harvested at indicated times. Cell lysates were immunoblotted with anti-PALMD (top panel), anti-phospho-p53(Ser46) (second panel), anti-p53 (third panel), or anti-tubulin (bottom panel)